Skip to main content
OpenTrials
Completed

NCT Number: NCT05899036

Early Feasibility Study of RapidPulseTM Aspiration System for Patients With Acute Ischemic Stroke

The goal of this clinical trial is to assess the initial safety and performance of the RapidPulseTM Aspiration System in patients experiencing acute ischemic stroke within 24 hours since the onset of stroke symptoms, or last known normal. Subject will undergo mechanical thrombectomy (a procedure to remove a clot in the brain which is preventing blood flow), with the RapidPulseTM Aspiration System. Participating in the trial is for 5-7 days or hospital discharge (whichever is earlier).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital de Clinicas Facultad de Medicina-Universidad Nacional de Asunción, Asunción, Paraguay

Loading trial locations.

About this study

The purpose of this prospective, multi-center, open label study of the RapidPulseTM Aspiration System is to assess the initial technical (performance), effectiveness and safety of the RapidPulseTM Aspiration System as frontline approach for patients with acute ischemic stroke due to large vessel occlusions identified within 24 hours of symptom onset (or last seen normal). The target sample size is 10 evaluable subjects with a maximum of 50 subjects. Subjects will undergo mechanical thrombectomy procedure and will have postoperative assessments completed at 24 hours and on Day 5-7 or upon hospital discharge. The primary endpoint is first pass reperfusion effect (FPE) as defined by mTICI ≥ 2c after one reperfusion attempt.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical diagnosis of acute ischemic stroke with symptom onset (or last seen normal) within 24 hours.
  • CTA, MRA or DSA demonstrating anterior large vessel occlusion involving the intracranial ICA, MCA M1 or M2 segments, basilar or vertebral artery
  • Target occlusion can be accessed by the RapidPulseTM 071 aspiration catheter assessed at the time of the index procedure. Enrollment will be defined by the successful navigation of the RapidPulseTM 071 aspiration catheter into the occlusion site.

Exclusion criteria

  • Known or suspected ICAD
  • Tandem occlusions

Treatment and study plan

RapidPulseTM Aspiration System

Device

The RapidPulseTM Aspiration System is designed to remove occlusive thrombus from the cerebral vasculature using pulsatile aspiration. The system is comprised of a sterile one-time use 071 catheter, a sterile one-time use tubing set and a multiuse aspiration pump console.

Other names: Aspiration Thrombectomy, Thrombectomy

Primary outcomes

  1. First Pass Reperfusion Effect (FPE)

    Time frame: Intra-procedural

    The number of subjects with mTICI ≥ 2c after one reperfusion attempt

Other outcomes

  1. Frontline technical success

    Time frame: Intra-procedural

    The number of subjects with mTICI ≥ 2b after the last pass with Study Device (no rescue therapy)

  2. Final mTICI score

    Time frame: Intra-procedural

    The final mTICI score (0-3) for all subjects after all passes (including any rescue therapy)

  3. Modified First Pass Reperfusion Effect (mFPE)

    Time frame: Intra-procedural

    The number of subjects with mTICI ≥ 2b after one device pass

  4. Device-related and procedure-related adverse events

    Time frame: Intra and post procedural (up to Day 5-7 or discharge whichever occurs earlier)

    Including vessel injury, distal emboli, emboli in new territory (ENT) and vessel spasm

Sponsors and collaborators

Lead sponsor

RapidPulse, Inc

Industry

Registry information

Official study title

PULSE-C: Early Feasibility Study of RapidPulseTM Aspiration System as Frontline Approach for Patients With Acute Ischemic Stroke Due to Large Vessel Occlusions

Acronym: PULSE-C

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Jun 12, 2023
Registry last updated
Jan 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.